Seven rheumatology researchers have authored a paper questioning the utility of the 2024 National Academies’ broad definition of long COVID.

NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Shares of Regeneron Pharmaceuticals Inc. slid 3.61% to $665.46 Tuesday, on what proved to be an all-around favorable trading ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the appointment of Robert E. Landry to its Board of Directors. Mr. Landry brings over three decades of financial and operational expertise in ...

NEW YORK, NY / ACCESS Newswire / February 10, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In Honeywell International Inc. v. 3G Licensing, S.A., Appeal No. 23-1354, the Federal Circuit held that under the obviousness standard of 35 U.S.C.

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Janus kinase inhibitors are an incredibly important, new tool that have exemplified both high efficacy and safety, according to a speaker at South Beach Symposium.In an interview with Healio, ...